Premium Nahrungsergänzungsmittel | artgerecht

Procollagen Type III N Propeptide (PIIINP) Explained

Procollagen Type III N Propeptide (PIIINP) is a biomarker reflecting collagen synthesis and tissue fibrosis. Elevated levels indicate increased connective tissue remodeling in organs.

Regular tips about health Regular tips about health

Things worth knowing about "Procollagen Type III N Propeptide"

Procollagen Type III N Propeptide (PIIINP) is a biomarker reflecting collagen synthesis and tissue fibrosis. Elevated levels indicate increased connective tissue remodeling in organs.

What is Procollagen Type III N Propeptide?

Procollagen Type III N Propeptide (abbreviated PIIINP) is a protein fragment released during the biosynthesis of collagen type III. Collagen is the most abundant structural protein in the human body and a key component of connective tissue, skin, blood vessel walls, liver, kidneys, and other organs. When new type III collagen is formed, the procollagen molecule is processed by enzymes, and the N-terminal propeptide (PIIINP) is cleaved off and released into the bloodstream. The concentration of PIIINP in the blood therefore reflects the rate of collagen synthesis and connective tissue remodeling.

Biological Function and Origin

Collagen type III is predominantly found in elastic tissues such as blood vessels, skin, and internal organs. During the synthesis of new collagen, a precursor molecule called procollagen is first produced. This molecule carries additional peptide extensions at both ends – the N-terminal and C-terminal propeptides. Enzymes known as procollagen peptidases cleave these propeptides once the collagen is incorporated into the extracellular matrix. The released PIIINP enters the bloodstream, where it can be measured.

Clinical Significance as a Biomarker

PIIINP is used in clinical diagnostics as a fibrosis marker and an indicator of connective tissue remodeling. Elevated PIIINP levels may indicate the following conditions:

Liver fibrosis and cirrhosis: In chronic liver diseases (e.g., caused by alcohol, hepatitis B or C), excess connective tissue is deposited in the liver. PIIINP is a sensitive marker for the activity of liver fibrosis.
Heart failure and cardiac fibrosis: Cardiac remodeling processes are often associated with elevated PIIINP levels.
Pulmonary fibrosis: Lung diseases with fibrous tissue remodeling can lead to an increase in PIIINP.
Renal fibrosis: Chronic kidney diseases with fibrotic changes are often accompanied by altered PIIINP levels.
Growth processes in children: Physiologically elevated PIIINP levels in children and adolescents are normal due to active growth.
Monitoring during growth hormone therapy: PIIINP is used to detect overdosing during growth hormone treatment.

Diagnosis and Measurement

PIIINP is measured from a simple blood sample (serum or plasma) using an immunoassay. Testing is typically performed as part of extended liver diagnostics, monitoring of chronic organ diseases, or when systemic fibrotic processes are suspected. Reference values may vary slightly between laboratories and assay methods. In adults, values below 8–10 µg/L are generally considered normal, with sex- and age-specific differences to be taken into account.

Factors Influencing PIIINP Levels

Age (elevated values during growth phases)
Pregnancy
Physical activity
Inflammatory conditions
Treatment with growth hormones or anabolic steroids

Treatment and Clinical Use

PIIINP itself is not a treatment target but rather a diagnostic and prognostic marker. It is used to:

Non-invasively assess the progression of liver fibrosis, thereby reducing the need for liver biopsy.
Monitor treatment response in chronic liver diseases.
Detect the risk of overdosing during growth hormone therapy.
Track fibrotic processes in heart failure, lung disease, or kidney disease.

Any treatment is always directed at the underlying condition causing the elevated PIIINP level.

References

Gressner A. M., Weiskirchen R.: Modern pathogenetic concepts of liver fibrosis. Journal of Cellular and Molecular Medicine, 2006; 10(1): 76–99.
Rosenberg W. M. et al.: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 2004; 127(6): 1704–1713.
World Health Organization (WHO): Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. WHO, 2015. Available at: https://www.who.int

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.